Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Sells $58,618.30 in Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) major shareholder Ra Capital Management, L.P. sold 87,490 shares of the business’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $0.67, for a total transaction of $58,618.30. Following the completion of the sale, the insider owned 413,001 shares in the company, valued at approximately $276,710.67. This trade represents a 17.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Tuesday, May 12th, Ra Capital Management, L.P. sold 101,151 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.64, for a total transaction of $64,736.64.
• On Friday, May 8th, Ra Capital Management, L.P. sold 376,526 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.71, for a total transaction of $267,333.46.

Werewolf Therapeutics Trading Down 7.1%

Shares of HOWL opened at $0.54 on Friday. The firm has a market cap of $26.37 million, a P/E ratio of -0.44 and a beta of 0.41. Werewolf Therapeutics, Inc. has a 12-month low of $0.50 and a 12-month high of $2.38. The company’s 50-day moving average price is $0.81 and its 200 day moving average price is $0.82.

Werewolf Therapeutics (NASDAQ:HOWL) last released its earnings results on Thursday, May 7th. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.04. Equities research analysts forecast that Werewolf Therapeutics, Inc. will post -1.29 earnings per share for the current year.

Hedge Funds Weigh In On Werewolf Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in HOWL. Regal Investment Advisors LLC grew its position in shares of Werewolf Therapeutics by 93.3% during the fourth quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock worth $33,000 after buying an additional 25,389 shares in the last quarter. Vontobel Holding Ltd. grew its position in shares of Werewolf Therapeutics by 66.7% during the fourth quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock worth $38,000 after buying an additional 24,003 shares in the last quarter. Qube Research & Technologies Ltd acquired a new position in shares of Werewolf Therapeutics during the second quarter worth about $48,000. AQR Capital Management LLC acquired a new position in shares of Werewolf Therapeutics during the first quarter worth about $79,000. Finally, Bridgeway Capital Management LLC grew its position in shares of Werewolf Therapeutics by 157.7% during the second quarter. Bridgeway Capital Management LLC now owns 102,000 shares of the company’s stock worth $111,000 after buying an additional 62,414 shares in the last quarter. 64.84% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on HOWL shares. Wall Street Zen downgraded Werewolf Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Monday, April 20th. Two equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $3.75.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.